At Levena BioPharma, we interface complex synthetic chemistry with antibody research providing our clients with the latest technologies and comprehensive services to advance ADC projects from discovery to IND. Our ADC platform encompasses: ADC screening tools; bioactive molecules (toxins) for research and in cGMP grade; optimized linker-toxins; conjugation services; ADC toxicity screening; and ADC optimization & processing.
Multitude Therapeutics (MTX) is a preclinical-stage business unit created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy.MTX focuses on developing novel antibody-drug conjugates (ADC) and immuno-oncology (I/O) (T cells and macrophages) based antibody therapeutics for solid and blood tumors… Read More
EAG Laboratories delivers a broad array of product development and analytical testing services to support biopharmaceutical development. EAG’ s team of biotech experts has worked with virtually every type of biomolecule, including recombinant, fusion and glycoproteins, monoclonal antibodies, antibody-drug conjugates oligonucleotides, and vaccines. We offer a comprehensive range of biopharmaceutical services from analytical characterization to routine release and stability testing utilizing well-established techniques.
LegoChem Biosiences is a clinical stage biotech with expertise in medicinal chemistry. It has several antibiotic programs for infectious disease with urgent needs and drugs in oncology and anticoagulant. It has extended its expertise to ADC and developed next-generation site-specific ADC platform with novel linker that improves stability of ADCs in blood circulation, effectively prevents premature drug release, efficiently facilitates liberation of the drug at targeted tumor cells and ultimately shows significant improved therapeutic index.
For over 25 years, Lonza has been helping emerging biotech and pharmaceutical companies improve and advance their products. Whether you are in the early stages of clinical development or providing commercial product to patients around the globe, Lonza supplies complete development services, industry-leading manufacturing, and broad technology platforms that enable products to reach their full potential…Read More
MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
Formosa Laboratories, a globally-recognized generic API supplier, is approved by regulatory authorities worldwide, including the EMEA, USFDA, PMDA, and COFEPRIS. Our ado-trastuzumab emtansine biosimilar, co-developed with Formosa Pharmaceuticals, has demonstrated high similarity to Kadcyla®… Read More